56 results on '"Albertsen, Peter C"'
Search Results
2. Screening for Prostate Cancer with Prostate-specific Antigen: The Journey Continues
3. PSA testing, cancer treatment, and prostate cancer mortality reduction: What is the mechanism?
4. How many cores are enough? Optimizing the transperineal prostate biopsy template
5. Prostate-specific Antigen Screening Using the Traditional Cut Point of 3 ng/ml: Con
6. Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer—29-Year Follow-up
7. William Halsted and Prostate Cancer Progression
8. Centers of Excellence: What are Realistic Goals?
9. Patient Decision-making: Where Are We Going?
10. Free-hand transperineal prostate biopsy provides acceptable cancer detection and minimizes risk of infection: evolving experience with a 10-sector template
11. Re: Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists
12. Active Surveillance: A Ten-year Journey
13. Re: 10-Year Outcomes After Monitoring, Surgery or Radiotherapy for Localized Prostate Cancer
14. Validation of a Contemporary Five-tiered Gleason Grade Grouping Using Population-based Data
15. Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis.
16. Reply to Michael Froehner, Rainer Koch, Manfred P. Wirth's Letter to the Editor re: Grace L. Lu-Yao, Peter C. Albertsen, Dirk F. Moore, Yong Lin, Robert S. DiPaola, Siu-Long Yao. Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer. Eur Urol 2015;68:805–11
17. Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis
18. Another Reason to Consider Active Surveillance
19. Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer
20. Better Survival After Curative Treatment for Screen-detected Prostate Cancer Compared with Clinical Diagnosis: A Real Effect or Lead-time Bias?
21. The Evolution of Self-Reported Urinary and Sexual Dysfunction over the Last Two Decades: Implications for Comparative Effectiveness Research
22. Prediction of Long-term Other-cause Mortality in Men With Early-stage Prostate Cancer: Results From the Prostate Cancer Outcomes Study
23. Re: Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer
24. Times, They Are a-Changing
25. Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist
26. Re: Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement
27. Timing of Curative Treatment for Prostate Cancer: A Systematic Review
28. It's Time to Change the Treatment Paradigm for Prostate Cancer!
29. Active Surveillance for Prostate Cancer: A Systematic Review of the Literature
30. Does Primary Androgen-Deprivation Therapy Delay the Receipt of Secondary Cancer Therapy for Localized Prostate Cancer?
31. Editorial Comment
32. Robot-assisted Radical Prostatectomy – Fake Innovation or the Real Deal?
33. How Best To Use Our Tools?
34. Risk-Based Prostate Cancer Screening
35. Measuring illness uncertainty in men undergoing active surveillance for prostate cancer
36. The Timing and Extent of Androgen Deprivation Therapy for Prostate Cancer: Weighing the Clinical Evidence
37. Patterns and Correlates of Prostate Cancer Treatment in Older Men
38. Use and Assessment of PSA in Prostate Cancer
39. Reply
40. The Unintended Burden of Increased Prostate Cancer Detection Associated With Prostate Cancer Screening and Diagnosis
41. A Statistical Evaluation of Rules for Biochemical Failure After Radiotherapy in Men Treated for Prostate Cancer
42. The Treatment Paradigm Shifts Again on Prostate Cancer
43. Prostate-cancer mortality in the USA and UK in 1975–2004: an ecological study
44. Hierarchical Changepoint Models for Biochemical Markers Illustrated by Tracking Postradiotherapy Prostate-Specific Antigen Series in Men With Prostate Cancer
45. Populations at high risk for prostate cancer
46. United States radiation oncologists’ and urologists’ opinions about screening and treatment of prostate cancer vary by region
47. Lessons learnt about early prostate cancer from large scale databases: population-based pearls of wisdom
48. Diagnosing and treating chronic prostatitis: do urologists use the four-glass test?
49. Expression of vascular endothelial growth factor receptors in human prostate cancer
50. Assessment of the Feasibility and Impact of Shared Decision Making in Prostate Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.